Intended for UK Healthcare Professionals only. Adverse Event Reporting information can be found at the bottom of the page.
This website contains promotional information

Medikinet® XL (methylphenidate hydrochloride)

Medikinet® XL can be used as part of a comprehensive treatment programme for attention deficit hyperactivity disorder (ADHD) in children aged 6 years of age and over and adults when remedial measures alone aren’t sufficient. 1

Dosing & administration in children

  • At the start of treatment with Medikinet® XL, careful dose titration is necessary
  • Starting dose: 10 mg daily taken with or after breakfast 1. Methylphenidate hydrochloride is absorbed much faster from Medikinet XL when the medicinal product is taken on an empty stomach. In this case, release may not be adequately sustained. Therefore, Medikinet XL should not be administered without food
  • Maximum daily dose: 60 mg 1
  • Titrate to an adequate dose then carry out a 6 week trial to determine the efficacy of the treatment for the patient2

Working with the school day

Medikinet® XL consists of an immediate-release component (50% of dose) and a modified-release component (50% of dose). This is why Medikinet XL 10 mg yields an immediate-release dose of 5 mg and an extended-release dose of 5 mg. 1

The extended-release portion of each dose is designed to maintain a treatment response through the afternoon, without the need for a midday dose. This is designed to work with the school day, delivering therapeutic plasma levels for around 8 hours. 1

If adults are new to Medikinet® XL (methylphenidate hydrochloride)

  • At the beginning of treatment, careful dose titration is necessary, starting at the lowest possible dose 1
  • Recommended starting daily dose is 10 mg daily, which may be increased, if necessary by weekly increments of 10 mg in the daily dose 1
  • The total daily dose should be given in two divided doses in the morning and at midday 1. Methylphenidate hydrochloride is absorbed much faster from Medikinet XL when the medicinal product is taken on an empty stomach. In this case, release may not be adequately sustained. Therefore, Medikinet XL should not be administered without food
  • Compared to children and adolescents, adult patients may require a higher daily dose, based on patient’s body weight. The maximum daily dose must not exceed 1mg/kg body weight. Regardless of body weight, a maximum daily dose of 80mg should not be exceeded 1

Working with a busy day

    The extended-release portion of each dose is designed to maintain a treatment response into the afternoon. Because adults may have further responsibilities into the evening Medikinet XL should be taken twice a day, to maintain the therapeutic effect into the evening. 1

Safety and Monitoring

For full safety information please refer to section 4 of the SmPC or click here.

Continuing therapy with Medikinet® XL (methylphenidate hydrochloride) for adults

Adult patients who’ve shown clear benefit from treatment with Medikinet® XL in childhood or adolescence may continue treatment into adulthood. Initially, this can be at the same daily dose (mg/day). Whether an adjustment is needed depends on how well it continues to work and it's tolerability. 1

Contact us

If you would like to find out more about our treatments or therapy area expertise, please contact us

References
  1. Medikinet® XL, Summary of Product Characteristics.
  2. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE Guideline 87.

Medikinet® XL

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions.

Adverse event reporting
Adverse events should be reported. Reporting forms and information can be found at the Yellow Card Scheme; https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should be reported to MEDICE UK at medicalinformation@medice.co.uk
Please retain the reported medication and packaging for further investigation by MEDICE UK.
Reporting side effects can provide more information on the safety of this medicine.